Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days for obtaining the report for the PDGFR Beta (5q33) Gene Rearrangement Test By FISH is typically 7-10 business days.

What are the prerequisites for the test PDGFR Beta (5q33) Gene Rearrangement Test By FISH

  • Specimen: Formalin-fixed, paraffin-embedded tissue block
  • Must be received within 5 days of collection
  • Requisition form must be completed and submitted with the specimen
  • Patient’s clinical history and relevant laboratory data must be provided

What are the measure values for the test PDGFR Beta (5q33) Gene Rearrangement Test By FISH

Measure Value Result
Normal Less than 2% of cells with rearrangement
Abnormal More than or equal to 2% of cells with rearrangement

What does this test PDGFR Beta (5q33) Gene Rearrangement Test By FISH identify?

  1. This test identifies rearrangements involving the PDGFR Beta gene located on chromosome 5q33.
  2. Fluorescence in situ hybridization (FISH) is used to detect any abnormalities in the gene structure.
  3. Rearrangements in the PDGFR Beta gene can be associated with certain types of cancer, particularly hematological malignancies.
  4. Identifying these rearrangements can help in diagnosis, prognosis, and treatment planning for patients with cancer.

Why is this test PDGFR Beta (5q33) Gene Rearrangement Test By FISH taken?

The PDGFR Beta (5q33) Gene Rearrangement Test By FISH is taken to detect any rearrangements in the PDGFR Beta gene located on chromosome 5q33. Rearrangements in this gene can lead to the development of certain cancers, particularly hematologic malignancies such as chronic myelomonocytic leukemia (CMML) and atypical chronic myeloid leukemia (aCML).

By identifying any rearrangements in the PDGFR Beta gene, healthcare providers can determine the most appropriate treatment options for patients with these types of cancers. This test is especially important in guiding targeted therapy decisions, as certain drugs have been specifically designed to target the abnormal PDGFR Beta gene.

No FAQs available.

Customer Google Rating